{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:46:02Z","timestamp":1778964362679,"version":"3.51.4"},"reference-count":28,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T00:00:00Z","timestamp":1269475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>We conducted a retrospective analysis of administration of nonoccupational HIV post\u2010exposure prophylaxis (nPEP) in a single centre where tracing and testing of the source of exposure were carried out systematically over a 10\u2010year period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Files of all nPEP requests between 1998 and 2007 were reviewed. Characteristics of the exposed and source patients, the type of exposure, and clinical and serological outcomes were analysed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>nPEP requests increased by 850% over 10 years. Among 910 events, 58% were heterosexual exposures, 15% homosexual exposures, 6% sexual assaults and 20% nonsexual exposures. In 208 events (23%), the source was reported to be HIV positive. In the remaining cases, active source tracing enabled 298 HIV tests to be performed (42%) and identified 11 HIV infections (3.7%). nPEP was able to be avoided or interrupted in 31% of 910 events when the source tested negative. Of 710 patients who started nPEP, 396 (56%) reported side effects, among whom 39 (5%) had to interrupt treatment. There were two HIV seroconversions, and neither was attributed to nPEP failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>nPEP requests increased over time. HIV testing of the source person avoided nPEP in 31% of events and was therefore paramount in the management of potential HIV exposures. Furthermore, it allowed active screening of populations potentially at risk for undiagnosed HIV infection, as shown by the increased HIV prevalence in these groups (3.7%) compared with a prevalence of 0.3% in Switzerland as a whole.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2010.00826.x","type":"journal-article","created":{"date-parts":[[2010,3,26]],"date-time":"2010-03-26T01:54:35Z","timestamp":1269568475000},"page":"584-592","source":"Crossref","is-referenced-by-count":37,"title":["Nonoccupational HIV post\u2010exposure prophylaxis: a 10\u2010year retrospective analysis"],"prefix":"10.1111","volume":"11","author":[{"given":"F","family":"Tissot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Erard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Cavassini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,9,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.20.9771-9775.2000"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.5.4265-4273.1998"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411033311801"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199611283352201"},{"key":"e_1_2_6_6_2","first-page":"929","article-title":"Case\u2010control study of HIV seroconversion in health care workers after percutaneous exposure to HIV\u2010infected blood","volume":"44","author":"Centers for Disease Control.","year":"1995","journal-title":"France, United Kingdom and United States, January 1988\u2013August 1994"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199711203372101"},{"issue":"2","key":"e_1_2_6_8_2","first-page":"1","article-title":"Antiretroviral postexposure prophylaxis after sexual, injection\u2010drug use, or other nonoccupational exposure to HIV in the United States","volume":"54","author":"Centers for Disease Control.","year":"2005","journal-title":"Morb Mortal Wkly Rep"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704103361512"},{"key":"e_1_2_6_10_2","first-page":"433","article-title":"Antiretroviral prophylaxis for community exposure to the human immunodeficiency virus in Switzerland, 1997\u20132000","volume":"131","author":"Bernasconi E","year":"2001","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_6_11_2","first-page":"695","article-title":"Post\u2010exposure prophylaxis after occupational and non\u2010occupational exposures to HIV","volume":"12","author":"Rey D","year":"2000","journal-title":"an overview of the policies implemented in 27 European countries"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.271.18.1436"},{"key":"e_1_2_6_13_2","first-page":"641","article-title":"Offering HIV prophylaxis to people who have been sexually assaulted","volume":"162","author":"Wiebe ER","year":"2000","journal-title":"16 months' experience in a sexual assault service"},{"key":"e_1_2_6_14_2","first-page":"214","article-title":"Postexposure prophylaxis after sexual assaults","volume":"32","author":"Teixeira Garcia M","year":"2005","journal-title":"a prospective cohort study"},{"key":"e_1_2_6_15_2","first-page":"4","article-title":"Preliminary recommendations for HIV post\u2010exposure prophylaxis outside the medical setting","volume":"50","author":"Swiss Federal Office of Public Health.","year":"1997","journal-title":"Bull OFSP"},{"key":"e_1_2_6_16_2","first-page":"712","article-title":"Recommendations for HIV post\u2010exposure prophylaxis outside the medical setting \u2013 update 2006","volume":"36","author":"Swiss Federal Office of Public Health.","year":"2006","journal-title":"Bull OFSP"},{"key":"e_1_2_6_17_2","first-page":"707","article-title":"Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure","volume":"183","author":"Kahn JO","year":"2001","journal-title":"the San Francisco PEP study"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00483.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200403260-00010"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200404150-00010"},{"key":"e_1_2_6_21_2","first-page":"1608","article-title":"Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure","volume":"184","author":"Roland ME","year":"2001","journal-title":"identification and characterization of the source of exposure"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.12.1516-a"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318198a96a"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.1.46"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/497268"},{"key":"e_1_2_6_26_2","unstructured":"AlmedaJ CasabonaBJ SimonBet al. Proposed recommendations for the management of HIV post\u2010exposure prophylaxis after sexual injecting drug or other exposures in Europe. Available athttp:\/\/www.eurosurveillance.org\/em\/v09n06\/0906\u2010223.asp(accessed 2 December 2008)."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200205240-00011"},{"key":"e_1_2_6_28_2","unstructured":"Swiss Federal Office of Public Health.Characteristics of HIV epidemics in Switzerland in 2008. Available athttp:\/\/www.bag.admin.ch(accessed 21 April 2009)."},{"key":"e_1_2_6_29_2","first-page":"2524","article-title":"The trap","volume":"167","author":"Giulieri S","year":"2007","journal-title":"professional exposure to human immunodeficiency virus antibody-negative blood with high viral load"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2010.00826.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2010.00826.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T21:03:04Z","timestamp":1698699784000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2010.00826.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,3]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1468-1293.2010.00826.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2010.00826.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,3]]}}}